The changing landscape of the clinical value of the PM/Scl autoantibody system
Open Access
- 1 January 2009
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 11 (2), 106
- https://doi.org/10.1186/ar2646
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A dermatomyositis and scleroderma overlap syndrome with a remarkable high titer of anti-exosome antibodiesReumatismo, 2011
- PM1-Alpha ELISA: The assay of choice for the detection of anti-PM/Scl autoantibodies?Autoimmunity Reviews, 2009
- Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patientsArthritis Research & Therapy, 2009
- Update on autoantibodies in systemic sclerosisCurrent Opinion in Rheumatology, 2007
- Novel aspects of autoantibodies to the PM/Scl complex: Clinical, genetic and diagnostic insightsAutoimmunity Reviews, 2007
- Advances and Applications of Multiplexed Diagnostic Technologies in Autoimmune DiseasesLupus, 2006
- Autoantibodies in Systemic SclerosisSeminars in Arthritis and Rheumatism, 2005
- Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigenArthritis Research & Therapy, 2005
- PM–Scl‐75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndromeArthritis & Rheumatism, 2004
- The clinical relevance of autoantibodies in sclerodermaArthritis Research & Therapy, 2003